On November 13, 2017, the Canadian Agency for Drugs and Technologies in Health (CADTH) released a new CDR Update (Issue 130).
Revised Procedure for the CADTH Common Drug Review Resubmissions
In August 2017, CADTH invited stakeholder comments and feedback on a proposal to revise the resubmission requirements for its Common ... Read More
News & Events
16
Nov2017
08
Nov2017
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of October 31, 2017:
46 negotiations are currently underway with 2 new files added since the last update of September 30, 2017:
Gazyva (obinutuzumab): Used to treat follicular lymphoma
Lynparza (olaparib): Used to treat ... Read More
08
Nov2017
INESSS Releases Additional Information on the Continuous Evaluation Process
/ INESSS, Quebec, What's New
On November 7, 2017, Québec’s Institut national d’excellence en santé et en services sociaux (INESSS) released a notice to manufacturers announcing further details on the continuous evaluation process.
INESSS would like to inform manufacturers that as of November 1, 2017, new terms and conditions apply for manufacturers who wish to request ... Read More
08
Nov2017
The ongoing debate about repealing existing public and private drug programs and replacing them with a one-size-fits-all national pharmacare program returned to the headlines with the release of a wide-ranging report from the Parliamentary Budget Officer (PBO) which estimates the cost of a federally administered universal pharmacare plan.
The PBO study ... Read More
03
Nov2017
INESSS Releases List of Drug Products Currently Being Reviewed Under the Continuous Evaluation Process
/ INESSS, Quebec, What's New
On November 2, 2017, Québec’s Institut national d’excellence en santé et en services sociaux (INESSS) announced they have now published the list of drug products currently undergoing review under their new continuous evaluation process on their website.
Citizens, health professionals, patients and their caregivers, as well as their associations or ... Read More
01
Nov2017
The Patented Medicine Prices Review Board (PMPRB), in accordance with sections 89 and 100 of the Patent Act, released its Annual Report for the year ended December 31, 2016. The Annual Report is an extensive document that reviews all of the PMPRB’s major activities, analyses of the prices of patented ... Read More
31
Oct2017
PDCI is excited to announce another great addition to the PDCI team: John-Paul Dowson, Director, Reimbursement Strategy
/ PDCI, What's New
It is with great pleasure to announce after several months of a successful strategic partnership with Roubaix Strategies Inc. (RSI), John-Paul Dowson is formally joining the PDCI team as our new Director of Reimbursement Strategy.
John-Paul brings more than 20 years of senior experience working in the health and pharmaceutical sectors. ... Read More
30
Oct2017
We are pleased to announce that effective October 30, 2017 Jennifer Haig has joined PDCI Market Access Inc. as Manager, HTA and Health Economics.
Jen joins our growing HTA team and brings extensive experience with Pharmacoeconomic and Budget Impact modelling. Prior to joining PDCI, Jen was a market access and health ... Read More
18
Oct2017
The Régie de l’assurance maladie du Québec (RAMQ) released its October update of the List of Medications on October 18, 2017, effective immediately.
For more information and to see the list update schedule, please visit the RAMQ website.
17
Oct2017
INESSS Releases Additional Information on the Continuous Evaluation of Drug Products – Mandatory Notification
/ INESSS, Quebec, What's New
On October 12, 2017, Québec’s Institut national d’excellence en santé et en services sociaux (INESSS) released a notice to manufacturers announcing the details on the process for the mandatory notification required for submissions. As of November 1, 2017, manufacturers are required to inform INESSS at least 2 months in advance ... Read More